Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

Phase 4RecruitingNCT07132515

Mansoura University100 enrolled

Overview

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

100

Conditions

Cirrhosis HCC - Hepatocellular Carcinoma Portal Vein Thrombosis

Interventions

Enoxaparin, warfarrin, or apixabanDRUG

Enoxaparin, warfarrin, or apixaban

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B Exclusion Criteria: * Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding

Locations (1)

Mansoura University Hospitals

Al Mansurah, Dakahlia Governorate, Egypt

RECRUITING

Outcomes

Primary Outcomes

Portal vein thrombosis

determine if thrombus resolved or not on anticcoagulant by triphasic CT

Time frame: 6 months

Central Contacts

Dalia Elsayed Ganady, MBBS

CONTACT

+201095529264 dalia.tawfik97@gmail.com

Hatem Elalfy, PhD

CONTACT

+201224790518 elalfy2004@mans.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.